<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200421047152N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-30</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of endometrial Scratching on pregnancy outcome after intrauterine insemination</public_title>
      <acronym></acronym>
      <scientific_title>Effect of endometrial Scratching on pregnancy outcome after intrauterine insemination (IUI) in patients with previous IUI failure, a randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>192</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67801</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Stratified randomization will be done according to age (above and below 35 years)  and using permuted blocks with a size of 4. The random list is generated by the website www.sealedenvelope.com software and will be given to an independent third party for concealment and will be revealed to the researcher respectively, Blinding description: Patients will be aware of being in a study with two groups, with and without endometrial scraping, but will not know whether endometrial scraping is being performed for them. To reach this goal patients in the control group will undergo a vaginal examination with a speculum and a cervical scraper will enter into the posterior fornix without scratching. Patients in the control group will not be informed about the intervention type.</study_design>
      <phase>3</phase>
      <hc_freetext>Infertility needs intrauterine insemination (IUI).</hc_freetext>
      <i_freetext>Intervention 1: Endometrial scratching intervention group: Endometrial scratching is done in the intrauterine sperm injection (IUI) cycle on day 5 or 6 from the beginning of the menstrual cycle. To perform endometrial scratching, the patient is placed in a lithotomy position. Then, the speculum is slowly placed in the vagina to expose the cervix, and with the use of a flexible catheter, the endometrium is scratched in a circular position after performing aspiration. The circular movement of the catheter starts and ends in 12 o'clock position, and then the catheter is removed. If the catheter does not pass through the tenaculum, the anterior edge of the cervix is used to grasp the. According to the level of Anti-Müllerian Hormone (AMH) and Ovarian Reserve Count (AFC), letrozole, Cinnal F, or Menstrual Gonadotropin (HMG) is used to stimulate the ovaries, depending on the initial response to stimulation. After starting the drugs, the follicle size is monitored. When the size of the follicles is greater than or equal to 18, two ampoules of human chorionic gonadotropin (HCG) are prescribed to release the egg, and the patient undergoes IUI after 36 hours. Intervention 2: Control group: Patients in this group will undergo a vaginal examination with a speculum and a cervical scraper will enter into the posterior fornix without scratching. According to the level of Anti-Müllerian Hormone (AMH) and Ovarian Reserve Count (AFC), letrozole, Cinnal F, or Menstrual Gonadotropin (HMG) is used to stimulate the ovaries, depending on the initial response to stimulation. After starting the drugs, the follicle size is monitored. When the size of the follicles is greater than or equal to 18, two ampoules of human chorionic gonadotropin (HCG) are prescribed to release the egg, and the patient undergoes IUI after 36 hours.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Behnaz Mohabatian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bagh-ferdous station, Molavi street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1168743514</zip>
        <telephone>+98 21 86709</telephone>
        <email>dr.mohabatian@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahnaz Ashrafi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bagh-ferdous station, Molavi street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1168743514</zip>
        <telephone>+98 21 86709</telephone>
        <email>ashrafi.m@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 20-42 year
Unexplained infertility or mild male factor infertility
Failure of at least two previous intrauterine insemination (IUI) cycles</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>42 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Presence of endometriosis in stage 3 and 4 diagnosed by ultrasound
Sever male factor infertility
Underlying metabolic disease (hyperprolactinemia, thyroid disorder or any known metabolic disease)
Ovarian follicle-stimulating hormone (FSH) level &gt; 12
Body mass measurement &gt; 30</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z31.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Artificial insemination</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Endometrial scratching intervention group: Endometrial scratching is done in the intrauterine sperm injection (IUI) cycle on day 5 or 6 from the beginning of the menstrual cycle. To perform endometrial scratching, the patient is placed in a lithotomy position. Then, the speculum is slowly placed in the vagina to expose the cervix, and with the use of a flexible catheter, the endometrium is scratched in a circular position after performing aspiration. The circular movement of the catheter starts and ends in 12 o'clock position, and then the catheter is removed. If the catheter does not pass through the tenaculum, the anterior edge of the cervix is used to grasp the. According to the level of Anti-Müllerian Hormone (AMH) and Ovarian Reserve Count (AFC), letrozole, Cinnal F, or Menstrual Gonadotropin (HMG) is used to stimulate the ovaries, depending on the initial response to stimulation. After starting the drugs, the follicle size is monitored. When the size of the follicles is greater than or equal to 18, two ampoules of human chorionic gonadotropin (HCG) are prescribed to release the egg, and the patient undergoes IUI after 36 hours.</i_keyword>
      <i_keyword>Control group: Patients in this group will undergo a vaginal examination with a speculum and a cervical scraper will enter into the posterior fornix without scratching. According to the level of Anti-Müllerian Hormone (AMH) and Ovarian Reserve Count (AFC), letrozole, Cinnal F, or Menstrual Gonadotropin (HMG) is used to stimulate the ovaries, depending on the initial response to stimulation. After starting the drugs, the follicle size is monitored. When the size of the follicles is greater than or equal to 18, two ampoules of human chorionic gonadotropin (HCG) are prescribed to release the egg, and the patient undergoes IUI after 36 hours.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Clinical pregnancy rate. Timepoint: 5-6 weeks after IUI. Method of measurement: Transvaginal sonography.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Live birth rate. Timepoint: 28 weeks of pregnancy. Method of measurement: Phone based interview.</sec_outcome>
      <sec_outcome>Chemical pregnancy rate. Timepoint: 14 days after IUI. Method of measurement: Measurement of beta human chorionic gonadotropin serum level (Beta HCG).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-01-11</approval_date>
        <contact_name>IUMS Biomedical Research Ethics Committee</contact_name>
        <contact_address>Next to Milad Tower ,Hemat Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
